Plasminogen activator for the treatment of acute inflammatory and chronic interstitial lung diseases

Production of a recombinant chimeric fusion protein, consisting of human plasminogen activator (urokinase or u-PA) and human hydrophobic surfactant protein (SP-B, SP-C).<br>

Persistent suppression of alveolar fibrinolytic activity and the resulting permanent intra-alveolar fibrin deposition play an important pathomechanistic role in acute inflammatory and chronic interstitial lung diseases. In this process, the polymerization of fibrinogen to fibrin in the presence of lung surfactant causes incorporation of the surfactant into the growing fibrin matrix, which is associated with loss of surface activity, an altered fibrin structure, and enhanced resistance of fibrin to fibrinolytic proteases. In addition, the blocking of u-PA dependent processes is also linked with reduced activation of hepatocyte growth factor (HGF), which protects the epithelium.

Further Information: PDF

TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12

Contact
Dr. Peter Stumpf